Abstract
Anticonvulsant and neuroprotective effects of agonist and antagonist of metabotropic glutamate receptors (mGluRs) have been known for more than 10 years from multiple studies. However, it is not certain whether these candidate drugs are also antiepileptic and antiepileptogenic, as few studies included the chronic stages to determine whether spontaneous recurrent seizures could be prevented or stopped. Even in the acute stage, differences in experimental design such as timing and route of administration of candidate drugs, age, species and strain of experimental animal and experimental model make it difficult to determine the anticonvulsant and neuroprotective effects of each candidate drug. This paper, reviews in vivo neuropharmacological studies on agonsists and antagonists of mGluRs in different seizure and epilepsy models in last more than ten years. By combining with our neuropharmacological studies on the effect of mGluR agonists and antagonists in the mouse pilocarpine model of temporal lobe epilepsy, an ideal model for future development of mGluR agonists and antagonists as antiepileptogenic drugs will be proposed.
Keywords: Ionotropic glutamate receptors, epileptogenesis, kindling, seizures, epilepsy, pilocarpine model, status epilepticus
Current Neuropharmacology
Title: Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Volume: 3 Issue: 4
Author(s): F. R. Tang
Affiliation:
Keywords: Ionotropic glutamate receptors, epileptogenesis, kindling, seizures, epilepsy, pilocarpine model, status epilepticus
Abstract: Anticonvulsant and neuroprotective effects of agonist and antagonist of metabotropic glutamate receptors (mGluRs) have been known for more than 10 years from multiple studies. However, it is not certain whether these candidate drugs are also antiepileptic and antiepileptogenic, as few studies included the chronic stages to determine whether spontaneous recurrent seizures could be prevented or stopped. Even in the acute stage, differences in experimental design such as timing and route of administration of candidate drugs, age, species and strain of experimental animal and experimental model make it difficult to determine the anticonvulsant and neuroprotective effects of each candidate drug. This paper, reviews in vivo neuropharmacological studies on agonsists and antagonists of mGluRs in different seizure and epilepsy models in last more than ten years. By combining with our neuropharmacological studies on the effect of mGluR agonists and antagonists in the mouse pilocarpine model of temporal lobe epilepsy, an ideal model for future development of mGluR agonists and antagonists as antiepileptogenic drugs will be proposed.
Export Options
About this article
Cite this article as:
Tang R. F., Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?, Current Neuropharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157015905774322525
DOI https://dx.doi.org/10.2174/157015905774322525 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pharmacogenomics: The Influence of Genomic Variation on Drug Response
Current Topics in Medicinal Chemistry AMPA Receptor Antagonists for the Treatment of Stroke
Current Drug Targets - CNS & Neurological Disorders Perspective on mTOR-dependent Protection in Status Epilepticus
Current Neuropharmacology Classical and New Renin-Angiotensin Signalling in Atherosclerosis
Current Signal Transduction Therapy Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry 3D-QSAR Study of Some Heterocyclic Sulfonamide Analogs as hCAII Inhibitors
Letters in Drug Design & Discovery Purinergic Signalling and Neurological Diseases: An Update
CNS & Neurological Disorders - Drug Targets FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals Methylphenidate (Ritalin): What Makes it so Widely Prescribed During the Last 60 Years?
Current Drug Therapy PET Radiotracers for Molecular Imaging of Serotonin 5-HT<sub>1A</sub> Receptors
Current Medicinal Chemistry GABA-A Receptor Complex and Memory Processes
Current Topics in Medicinal Chemistry Recent Advances in Antiepileptic Herbal Medicine
Current Neuropharmacology Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives
Current Neuropharmacology Gene Therapy for Neuroprotection and Neurorestoration (Part I)
Current Gene Therapy Evolution of the Human Ion Channel Set
Combinatorial Chemistry & High Throughput Screening